BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26369969)

  • 21. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH; Tarbet EB; Babu YS; Klumpp K; Morrey JD
    Antiviral Res; 2010 Oct; 88(1):38-44. PubMed ID: 20633577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
    Liu Q; Ma J; Strayer DR; Mitchell WM; Carter WA; Ma W; Richt JA
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):165-9. PubMed ID: 24350808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.
    Yang P; Gu H; Zhao Z; Wang W; Cao B; Lai C; Yang X; Zhang L; Duan Y; Zhang S; Chen W; Zhen W; Cai M; Penninger JM; Jiang C; Wang X
    Sci Rep; 2014 Nov; 4():7027. PubMed ID: 25391767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Suzuki S; Shichinohe S; Itoh Y; Nakayama M; Ishigaki H; Mori Y; Ogata-Nakahara A; Nguyen CT; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antiviral Res; 2020 Jun; 178():104790. PubMed ID: 32272175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
    Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
    PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.
    Baranovich T; Burnham AJ; Marathe BM; Armstrong J; Guan Y; Shu Y; Peiris JM; Webby RJ; Webster RG; Govorkova EA
    J Infect Dis; 2014 May; 209(9):1343-53. PubMed ID: 24133191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-influenza virus activity of peramivir in mice with single intramuscular injection.
    Bantia S; Arnold CS; Parker CD; Upshaw R; Chand P
    Antiviral Res; 2006 Jan; 69(1):39-45. PubMed ID: 16325932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
    Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
    Marjuki H; Mishin VP; Chesnokov AP; Jones J; De La Cruz JA; Sleeman K; Tamura D; Nguyen HT; Wu HS; Chang FY; Liu MT; Fry AM; Cox NJ; Villanueva JM; Davis CT; Gubareva LV
    J Infect Dis; 2015 Jan; 211(2):249-57. PubMed ID: 25124927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.
    Kitano M; Itoh Y; Ishigaki H; Nakayama M; Ishida H; Pham VL; Arikata M; Shichinohe S; Tsuchiya H; Kitagawa N; Kobayashi M; Yoshida R; Sato A; Le QM; Kawaoka Y; Ogasawara K
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4795-803. PubMed ID: 24913156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
    Marathe BM; Mostafa HH; Vogel P; Pascua PNQ; Jones JC; Russell CJ; Webby RJ; Govorkova EA
    Antiviral Res; 2017 Dec; 148():20-31. PubMed ID: 29100887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
    Ding Y; Dou J; Teng Z; Yu J; Wang T; Lu N; Wang H; Zhou C
    Arch Virol; 2014 Dec; 159(12):3269-78. PubMed ID: 25078390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
    Boltz DA; Ilyushina NA; Arnold CS; Babu YS; Webster RG; Govorkova EA
    Antiviral Res; 2008 Nov; 80(2):150-7. PubMed ID: 18573280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment.
    Li Z; Li R; Li J; Xie H; Hao Y; Du Q; Chen T; Li Y; Chen R; Yang Z; Zhong N
    BMC Infect Dis; 2016 Jul; 16():325. PubMed ID: 27392915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus.
    Xu L; Bao L; Li F; Gu S; Lv Q; Yuan J; Xu Y; Zhu H; Deng W; Li Y; Yao Y; Yu P; Gao Z; Qin C
    J Gen Virol; 2015 Jan; 96(Pt 1):46-51. PubMed ID: 25274854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.
    Taniguchi K; Ando Y; Nobori H; Toba S; Noshi T; Kobayashi M; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
    Sci Rep; 2019 Mar; 9(1):3466. PubMed ID: 30837531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
    Tsai AW; McNeil CF; Leeman JR; Bennett HB; Nti-Addae K; Huang C; Germann UA; Byrn RA; Berlioz-Seux F; Rijnbrand R; Clark MP; Charifson PS; Jones SM
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6007-16. PubMed ID: 26169418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
    Sidwell RW; Smee DF; Huffman JH; Barnard DL; Bailey KW; Morrey JD; Babu YS
    Antimicrob Agents Chemother; 2001 Mar; 45(3):749-57. PubMed ID: 11181355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.